GSB Wealth Management LLC Raises Stake in Moderna, Inc. (NASDAQ:MRNA)

GSB Wealth Management LLC boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 94.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 10,301 shares of the company’s stock after purchasing an additional 5,009 shares during the period. GSB Wealth Management LLC’s holdings in Moderna were worth $428,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Public Sector Pension Investment Board boosted its holdings in shares of Moderna by 66.8% in the second quarter. Public Sector Pension Investment Board now owns 13,880 shares of the company’s stock valued at $1,648,000 after acquiring an additional 5,557 shares in the last quarter. Evergreen Capital Management LLC purchased a new stake in Moderna during the second quarter worth about $247,000. Marshall Wace LLP boosted its holdings in Moderna by 295.5% during the second quarter. Marshall Wace LLP now owns 35,200 shares of the company’s stock worth $4,180,000 after buying an additional 26,300 shares in the last quarter. AXA S.A. boosted its holdings in Moderna by 1.0% during the second quarter. AXA S.A. now owns 204,989 shares of the company’s stock worth $24,342,000 after buying an additional 1,947 shares in the last quarter. Finally, AQR Capital Management LLC boosted its holdings in Moderna by 32.0% during the second quarter. AQR Capital Management LLC now owns 5,083 shares of the company’s stock worth $604,000 after buying an additional 1,232 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on MRNA. Leerink Partners decreased their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Wolfe Research assumed coverage on shares of Moderna in a research report on Friday, November 15th. They set an “underperform” rating and a $40.00 target price for the company. Piper Sandler restated an “overweight” rating and set a $69.00 target price (down previously from $115.00) on shares of Moderna in a research report on Monday, November 18th. HSBC upgraded shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 target price for the company in a research report on Monday, November 18th. Finally, UBS Group cut their target price on shares of Moderna from $108.00 to $96.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Four equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $75.58.

Moderna Stock Down 2.3 %

MRNA opened at $41.41 on Friday. Moderna, Inc. has a 12-month low of $31.94 and a 12-month high of $170.47. The firm’s fifty day moving average price is $40.60 and its 200 day moving average price is $64.04. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion for the quarter, compared to analysts’ expectations of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s revenue was up 3.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.39) earnings per share. On average, equities research analysts anticipate that Moderna, Inc. will post -9.27 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 2,664 shares of company stock valued at $115,210. Company insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.